

David M Mutch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5708025/publications.pdf>

Version: 2024-02-01

167
papers

6,902
citations

94433

37
h-index

71685

76
g-index

172
all docs

172
docs citations

172
times ranked

8846
citing authors

#	ARTICLE	IF	CITATIONS
1	Guiding Global Best Practice in Personalized Nutrition Based on Genetics: The Development of a Nutrigenomics Care Map. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2022, 122, 259-269.	0.8	18
2	Polymorphisms in the stearoyl-CoA desaturase gene modify blood glucose response to dietary oils varying in MUFA content in adults with obesity. <i>British Journal of Nutrition</i> , 2022, 127, 503-512.	2.3	2
3	Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 379-389.	0.8	28
4	Tumor Lysis Syndrome in a Patient With Metastatic Endometrial Cancer Treated With Lattice Stereotactic Body Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2022, 7, 100797.	1.2	5
5	GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress. <i>Molecular Cancer Research</i> , 2022, 20, 265-279.	3.4	19
6	Impact of the COVID-19 pandemic on referral to and delivery of gynecologic oncology care. <i>Gynecologic Oncology Reports</i> , 2022, 39, 100928.	0.6	7
7	Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 968-977.	1.6	38
8	Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study. <i>Gynecologic Oncology</i> , 2022, 164, 428-436.	1.4	5
9	Effects of the WRITE Symptoms Interventions on Symptoms and Quality of Life Among Patients With Recurrent Ovarian Cancers: An NRG Oncology/GOG Study (GOG-0259). <i>Journal of Clinical Oncology</i> , 2022, 40, 1464-1473.	1.6	10
10	The IARC Perspective on Cervical Cancer Screening. <i>New England Journal of Medicine</i> , 2022, 386, 607-608.	27.0	1
11	The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer. <i>BMC Cancer</i> , 2022, 22, 263.	2.6	3
12	The impact of tumor size and histology on local control when utilizing high-dose-rate interstitial brachytherapy for gynecologic malignancies. <i>Gynecologic Oncology</i> , 2022, , .	1.4	0
13	GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1348-1359.	4.1	5
14	TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3289-3300.	1.6	19
15	Association between rs174537 FADS1 polymorphism and immune cell profiles in abdominal and femoral subcutaneous adipose tissue: an exploratory study in adults with obesity. <i>Adipocyte</i> , 2021, 10, 124-130.	2.8	3
16	Abstract PO045: Inhibition of GAS6/AXL improves efficacy of HER2 inhibitor trastuzumab in uterine serous cancer. , 2021, , .		0
17	The role of endometrial sampling for surveillance of recurrence in postmenopausal patients with medically inoperable stage I endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2021, 35, 100694.	0.6	3
18	The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 287-298.	329.8	65

#	ARTICLE	IF	CITATIONS
19	The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women. <i>Gynecologic Oncology</i> , 2021, 160, 660-668.	1.4	9
20	Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. <i>Gynecologic Oncology</i> , 2021, 161, 113-121.	1.4	42
21	Impact of employment and insurance status on distress in gynecologic oncology patients. <i>Gynecologic Oncology</i> , 2021, 161, 477-482.	1.4	6
22	A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancy. <i>Gynecologic Oncology</i> , 2021, 161, 700-704.	1.4	4
23	Text-message-based behavioral weight loss for endometrial cancer survivors with obesity: A randomized controlled trial. <i>Gynecologic Oncology</i> , 2021, 162, 770-777.	1.4	9
24	Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer. <i>Cancers</i> , 2021, 13, 5877.	3.7	3
25	Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2020, 156, 423-429.	1.4	23
26	Prediction modelling of 1-year outcomes to a personalized lifestyle intervention for Canadians with metabolic syndrome. <i>Applied Physiology, Nutrition and Metabolism</i> , 2020, 45, 621-627.	1.9	1
27	A fellow-run clinic achieves similar patient outcomes as faculty clinics: A safe and feasible model for gynecologic oncology fellow education. <i>Gynecologic Oncology</i> , 2020, 159, 209-213.	1.4	3
28	Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1157-1161.	2.5	10
29	The Dawning of the Age of Personalized Medicine in Gynecologic Oncology. <i>Cancers</i> , 2020, 12, 3135.	3.7	2
30	The emerging role of precision medicine in the treatment of endometrial cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 87-93.	0.7	1
31	Proteogenomic Characterization of Endometrial Carcinoma. <i>Cell</i> , 2020, 180, 729-748.e26.	28.9	296
32	Modified frailty index is predictive of wound complications in obese patients undergoing gynecologic surgery via a midline vertical incision. <i>Gynecologic Oncology</i> , 2020, 157, 287-292.	1.4	11
33	FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival. <i>Gynecologic Oncology</i> , 2020, 157, 639-643.	1.4	57
34	Adipokines Deregulate Cellular Communication via Epigenetic Repression of <i>Gap Junction</i> Loci in Obese Endometrial Cancer. <i>Cancer Research</i> , 2019, 79, 196-208.	0.9	16
35	FADS1 genotype is distinguished by human subcutaneous adipose tissue fatty acids, but not inflammatory gene expression. <i>International Journal of Obesity</i> , 2019, 43, 1539-1548.	3.4	9
36	Patients with endometrial cancer continue to lack understanding of their risks for cancer. <i>Gynecologic Oncology Reports</i> , 2019, 29, 106-110.	0.6	6

#	ARTICLE	IF	CITATIONS
37	Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6-year follow-up study. <i>Gynecologic Oncology</i> , 2019, 155, 88-92.	1.4	10
38	Histogram analysis of en face scattering coefficient map predicts malignancy in human ovarian tissue. <i>Journal of Biophotonics</i> , 2019, 12, e201900115.	2.3	11
39	Factors influencing residents' interest in gynecologic oncology fellowship. <i>Gynecologic Oncology Reports</i> , 2019, 30, 100504.	0.6	5
40	Optical Resolution Photoacoustic Microscopy of Ovary and Fallopian Tube. <i>Scientific Reports</i> , 2019, 9, 14306.	3.3	17
41	Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1088-1097.	0.8	57
42	Type II endometrial cancers with minimal, non-invasive residual disease on final pathology: What should we do next?. <i>Gynecologic Oncology Reports</i> , 2019, 29, 20-24.	0.6	2
43	Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2317-2326.	27.0	326
44	Do gynecologic oncology patients with severely diminished renal function and urinary tract obstruction benefit from ureteral stenting or percutaneous nephrostomy?. <i>Gynecologic Oncology Reports</i> , 2019, 28, 136-140.	0.6	6
45	Treatment Compliance as a Major Barrier to Optimal Cervical Cancer Treatment in Guatemala. <i>Journal of Global Oncology</i> , 2019, 5, 1-5.	0.5	10
46	Clinical outcomes after isolated pelvic failure in cervical cancer patients treated with definitive radiation. <i>Gynecologic Oncology</i> , 2019, 153, 530-534.	1.4	10
47	p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenografts. <i>Scientific Reports</i> , 2019, 9, 4762.	3.3	19
48	Inpatient management of hypercalcemia portends a poor prognosis among gynecologic oncology patients: A trigger to initiate hospice care?. <i>Gynecologic Oncology Reports</i> , 2019, 28, 1-5.	0.6	4
49	GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2019, 153, 335-342.	1.4	6
50	Dicer1 Phosphomimetic Promotes Tumor Progression and Dissemination. <i>Cancer Research</i> , 2019, 79, 2662-2668.	0.9	10
51	SOX11 hypermethylation as a tumor biomarker in endometrial cancer. <i>Biochimie</i> , 2019, 162, 8-14.	2.6	14
52	Continuous epidural infusion in gynecologic oncology patients undergoing exploratory laparotomy: The new standard for decreased postoperative pain and opioid use. <i>Gynecologic Oncology</i> , 2019, 153, 356-361.	1.4	11
53	Impact of tumor histology on detection of pelvic and para-aortic nodal metastasis with ¹⁸ F-fluorodeoxyglucose-positron emission tomography in stage IB cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1351-1354.	2.5	8
54	Gynecologic Oncologists' Perceptions of Palliative Care and Associated Barriers: A Survey of the Society of Gynecologic Oncology. <i>Gynecologic and Obstetric Investigation</i> , 2019, 84, 50-55.	1.6	12

#	ARTICLE	IF	CITATIONS
55	Postpartum salpingectomy: a procedure whose time has come. American Journal of Obstetrics and Gynecology, 2019, 220, 8-9.	1.3	1
56	A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2019, 152, 548-553.	1.4	23
57	Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer. Molecular Cancer Therapeutics, 2019, 18, 389-398.	4.1	32
58	Squamous cell carcinoma of the vulva: a review of present management and future considerations. Expert Review of Anticancer Therapy, 2019, 19, 43-50.	2.4	9
59	Dietary EPA and DHA prevent changes in white adipose tissue omega-3 PUFA and oxylipin content associated with a Fads2 deficiency. Journal of Nutritional Biochemistry, 2019, 63, 140-149.	4.2	12
60	Lifestyle genomics and the metabolic syndrome: A review of genetic variants that influence response to diet and exercise interventions. Critical Reviews in Food Science and Nutrition, 2019, 59, 2028-2039.	10.3	33
61	A novel algorithm for network-based prediction of cancer recurrence. Genomics, 2019, 111, 17-23.	2.9	14
62	A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naïve patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial. Journal of Clinical Oncology, 2019, 37, 5500-5500.	1.6	29
63	MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization. Journal of the National Cancer Institute, 2018, 110, 517-526.	6.3	9
64	Lymphnode staging update in the American Joint Committee on Cancer 8th Edition cancer staging manual. Gynecologic Oncology, 2018, 150, 7-8.	1.4	17
65	A review of the associations between single nucleotide polymorphisms in taste receptors, eating behaviors, and health. Critical Reviews in Food Science and Nutrition, 2018, 58, 194-207.	10.3	115
66	Genes and Cancer. , 2018, , 493-527.e6.		0
67	The <i>FOXA2</i> transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer, 2018, 124, 65-73.	4.1	27
68	Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecologic Oncology, 2018, 148, 49-55.	1.4	14
69	Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer. British Journal of Cancer, 2018, 118, 72-78.	6.4	46
70	An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecologic Oncology, 2018, 148, 174-180.	1.4	83
71	Variants in <i>APOA5</i> and <i>ADIPOQ</i> and Moderate Improvements in Metabolic Syndrome during a One-Year Lifestyle Intervention. Lifestyle Genomics, 2018, 11, 80-89.	1.7	8
72	Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: a pilot study. Metabolomics, 2018, 14, 154.	3.0	22

#	ARTICLE	IF	CITATIONS
73	Pathology of cancers of the female genital tract including molecular pathology. International Journal of Gynecology and Obstetrics, 2018, 143, 93-108.	2.3	24
74	Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study. American Journal of Obstetrics and Gynecology, 2018, 219, 459.e1-459.e11.	1.3	12
75	SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth. Gynecologic Oncology, 2018, 151, 337-344.	1.4	3
76	Evaluation of Ovarian Cancer: Initial Application of Coregistered Photoacoustic Tomography and US. Radiology, 2018, 289, 740-747.	7.3	60
77	Single Nucleotide Polymorphisms in Taste Receptor Genes Are Associated with Snacking Patterns of Preschool-Aged Children in the Guelph Family Health Study: A Pilot Study. Nutrients, 2018, 10, 153.	4.1	21
78	Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2018, 151, 18-23.	1.4	18
79	Hereditary Ovarian Cancer and Risk Reduction. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 41, 31-48.	2.8	40
80	The promise of molecular staging for the future. Cancer, 2017, 123, 728-730.	4.1	3
81	Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma. Neoplasia, 2017, 19, 100-111.	5.3	27
82	Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva. Radiotherapy and Oncology, 2017, 122, 445-451.	0.6	12
83	Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors. Oncologist, 2017, 22, 377-e37.	3.7	25
84	Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing. Cancer, 2017, 123, 3261-3268.	4.1	72
85	Which patients with inoperable vulvar cancer may benefit from brachytherapy in addition to external beam radiation? A Surveillance, Epidemiology, and End Results analysis. Brachytherapy, 2017, 16, 831-840.	0.5	10
86	Unethical randomised controlled trial of cervical screening in India: US Freedom of Information Act disclosures. BMJ Global Health, 2017, 2, e000177.	4.7	1
87	Intensity modulated radiation therapy for squamous cell carcinoma of the vulva: Treatment technique and outcomes. Advances in Radiation Oncology, 2017, 2, 148-158.	1.2	33
88	Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. Gynecologic Oncology, 2017, 145, 519-525.	1.4	52
89	Synuclein β in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Cancer, 2017, 123, 1144-1155.	4.1	11
90	Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. Journal of the National Cancer Institute, 2017, 109, djw251.	6.3	28

#	ARTICLE	IF	CITATIONS
91	Two sisters with Mayer-Rokitansky-Küster-Hauser syndrome and serous adenocarcinoma of the ovary. <i>Gynecologic Oncology Reports</i> , 2017, 22, 13-15.	0.6	8
92	Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 147, 648-653.	1.4	21
93	Benefit of combination chemotherapy and radiation stratified by grade of stage IIIC endometrial cancer. <i>Gynecologic Oncology</i> , 2017, 147, 309-314.	1.4	22
94	Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2881-2891.	4.1	27
95	The effect of a multidisciplinary palliative care initiative on end of life care in gynecologic oncology patients. <i>Gynecologic Oncology</i> , 2017, 147, 460-464.	1.4	10
96	An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. <i>Gynecologic Oncology</i> , 2017, 147, 243-249.	1.4	61
97	Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. <i>Nature Medicine</i> , 2017, 23, 1046-1054.	30.7	145
98	Sex Differences in Blood HDL, the Total Cholesterol/HDL Ratio, and Palmitoleic Acid are Not Associated with Variants in Common Candidate Genes. <i>Lipids</i> , 2017, 52, 969-980.	1.7	19
99	Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: A review of the National Cancer Database. <i>Gynecologic Oncology</i> , 2017, 146, 572-579.	1.4	34
100	What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. <i>Cancer</i> , 2017, 123, 985-993.	4.1	13
101	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 192-193.	1.3	0
102	New therapies for advanced, recurrent, and metastatic endometrial cancers. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 19.	3.6	72
103	Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer. <i>PLoS ONE</i> , 2017, 12, e0190125.	2.5	14
104	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. <i>Oncotarget</i> , 2017, 8, 84579-84594.	1.8	23
105	Novel SOX17 frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutations. <i>Oncotarget</i> , 2017, 8, 68758-68768.	1.8	15
106	The clinical management of inoperable endometrial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 515-521.	2.4	16
107	Targeted therapy in endometrial cancer: Making progress. <i>Cancer</i> , 2016, 122, 3428-3429.	4.1	1
108	Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 766.e1-766.e9.	1.3	23

#	ARTICLE	IF	CITATIONS
109	MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair. <i>Human Mutation</i> , 2016, 37, 1004-1012.	2.5	6
110	Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology. <i>Scientific Reports</i> , 2016, 6, 22661.	3.3	6
111	Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3062-3068.	1.6	141
112	Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 141, 312-317.	1.4	75
113	Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy. <i>Gynecologic Oncology</i> , 2016, 141, 134-139.	1.4	37
114	AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer. <i>Oncotarget</i> , 2016, 7, 77291-77305.	1.8	26
115	Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic <i>via</i> hierarchical binding events at the plasma membrane. <i>Oncotarget</i> , 2016, 7, 31534-31549.	1.8	12
116	Polyunsaturated fatty acid regulation of adipocyte FADS1 and FADS2 expression and function. <i>Obesity</i> , 2015, 23, 725-728.	3.0	71
117	Effect of Tumor Stage on Surveillance Strategies After Treatment for Ovarian Cancer. <i>Journal of Gynecologic Surgery</i> , 2015, 31, 326-330.	0.1	0
118	Incorporation of Porcine Adenovirus 4 Fiber Protein Enhances Infectivity of Adenovirus Vector on Dendritic Cells: Implications for Immune-Mediated Cancer Therapy. <i>PLoS ONE</i> , 2015, 10, e0125851.	2.5	7
119	Premature Judgment of Uterine Morcellation: Look at the Data Before You Leap. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv283.	6.3	0
120	Awareness of the association between obesity and peri-operative risk among newly diagnosed patients with complex atypical hyperplasia and endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2015, 12, 41-44.	0.6	3
121	The future role of molecular staging in gynecologic cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2015, 131, S127-31.	2.3	3
122	Brachytherapy Is Associated With Improved Survival in Inoperable Stage I Endometrial Adenocarcinoma: A Population-Based Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 649-657.	0.8	34
123	Impact of an immunohistochemistry-based universal screening protocol for Lynch syndrome in endometrial cancer on genetic counseling and testing. <i>Gynecologic Oncology</i> , 2015, 137, 7-13.	1.4	47
124	Adjuvant radiotherapy in Stage II endometrial carcinoma: Is brachytherapy alone sufficient for local control?. <i>Brachytherapy</i> , 2015, 14, 427-432.	0.5	19
125	Molecular staging of gynecological cancer: What is the future?. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2015, 29, 776-789.	2.8	10
126	Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	32

#	ARTICLE	IF	CITATIONS
127	Associations between etiologic factors and mortality after endometrial cancer diagnosis: The NRG Oncology/Gynecologic Oncology Group 210 trial. <i>Gynecologic Oncology</i> , 2015, 139, 70-76.	1.4	23
128	Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2015, 138, 614-619.	1.4	9
129	Combined Microsatellite Instability, <i>MLH1</i> Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 4301-4308.	1.6	163
130	Molecular insights into the role of white adipose tissue in metabolically unhealthy normal weight and metabolically healthy obese individuals. <i>FASEB Journal</i> , 2015, 29, 748-758.	0.5	101
131	Polymerase ϵ (<i>POLE</i>) mutations in endometrial cancer: Clinical outcomes and implications for Lynch syndrome testing. <i>Cancer</i> , 2015, 121, 386-394.	4.1	142
132	The Role of FADS1/2 Polymorphisms on Cardiometabolic Markers and Fatty Acid Profiles in Young Adults Consuming Fish Oil Supplements. <i>Nutrients</i> , 2014, 6, 2290-2304.	4.1	30
133	A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2014, 135, 441-445.	1.4	69
134	Can Molecular Diagnostics Usher in a New Era for Screening, Diagnosis, and Treatment of Ovarian Cancer?. <i>Obstetrics and Gynecology</i> , 2014, 124, 870-872.	2.4	3
135	Hereditary gynecologic cancers. <i>International Journal of Gynecology and Obstetrics</i> , 2014, 124, 189-192.	2.3	14
136	Diagnosis and Management of Precancerous Cervical Lesions. <i>Current Obstetrics and Gynecology Reports</i> , 2014, 3, 128-135.	0.8	0
137	Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: A population-based analysis. <i>Gynecologic Oncology</i> , 2014, 133, 242-249.	1.4	18
138	Update on Prognostic Markers for Endometrial Cancer. <i>Women's Health</i> , 2014, 10, 277-288.	1.5	34
139	2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. <i>Gynecologic Oncology</i> , 2014, 133, 401-404.	1.4	251
140	Concomitant chemotherapy and radiation for the treatment of advanced-stage endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 134, 24-28.	1.4	16
141	Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial. <i>Gynecologic Oncology</i> , 2013, 129, 277-284.	1.4	185
142	Variation in the FADS1/2 gene cluster alters plasma $n\hat{6}$ PUFA and is weakly associated with hsCRP levels in healthy young adults. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2013, 89, 257-263.	2.2	33
143	Individual Saturated and Monounsaturated Fatty Acids Trigger Distinct Transcriptional Networks in Differentiated 3T3-L1 Preadipocytes. <i>Journal of Nutrigenetics and Nutrigenomics</i> , 2013, 6, 1-15.	1.3	43
144	Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup. <i>Journal of Clinical Oncology</i> , 2009, 27, 1419-1425.	1.6	645

#	ARTICLE	IF	CITATIONS
145	A Case Report Demonstrating Unambiguous Clinical Utility of Pet/CT Scanning in Recurrent Ovarian Cancer. <i>Case Reports in Oncology</i> , 2009, 2, 121-124.	0.7	1
146	<i>ATR</i> Mutation in Endometrioid Endometrial Cancer Is Associated With Poor Clinical Outcomes. <i>Journal of Clinical Oncology</i> , 2009, 27, 3091-3096.	1.6	71
147	Microsatellite Instability and Epigenetic Inactivation of MLH1 and Outcome of Patients With Endometrial Carcinomas of the Endometrioid Type. <i>Journal of Clinical Oncology</i> , 2007, 25, 2042-2048.	1.6	186
148	The Role of Genetic Testing for Cancer Susceptibility in Gynecologic Practice. <i>Obstetrics and Gynecology</i> , 2007, 110, 155-167.	2.4	26
149	Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2811-2818.	1.6	371
150	Society of Gynecologic Oncologists Education Committee Statement on Risk Assessment for Inherited Gynecologic Cancer Predispositions. <i>Gynecologic Oncology</i> , 2007, 107, 159-162.	1.4	257
151	Discussion: Accuracy of preoperative endometrial sampling by Huang et al. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 196, e1-e6.	1.3	1
152	Unraveling the Genetics of Human Obesity. <i>PLoS Genetics</i> , 2006, 2, e188.	3.5	130
153	RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 935-939.	1.3	32
154	Gemcitabine in cervical cancer. <i>Gynecologic Oncology</i> , 2003, 90, S8-S15.	1.4	33
155	Gemcitabine combination chemotherapy of ovarian cancer. <i>Gynecologic Oncology</i> , 2003, 90, S16-S20.	1.4	19
156	Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 5908-5913.	7.1	216
157	Surgical management of ovarian cancer. <i>Seminars in Oncology</i> , 2002, 29, 3-8.	2.2	40
158	Genotypic and phenotypic progression in endometrial tumorigenesis: Determining when defects in DNA mismatch repair and KRAS2 occur. <i>Genes Chromosomes and Cancer</i> , 2001, 32, 295-301.	2.8	18
159	No evidence for BCL10 mutation in endometrial cancers with microsatellite instability. <i>Human Mutation</i> , 2001, 17, 117-121.	2.5	4
160	Clinical significance of microsatellite instability in endometrial carcinoma. <i>Cancer</i> , 2000, 89, 1758-1764.	4.1	117
161	Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. <i>Cancer</i> , 1999, 85, 119-126.		44
162	Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers. <i>Genes Chromosomes and Cancer</i> , 1997, 18, 219-227.	2.8	98

#	ARTICLE	IF	CITATIONS
163	Frequent deletion of chromosome 1p sequences in an aggressive histologic subtype of endometrial cancer. <i>Human Molecular Genetics</i> , 1996, 5, 1017-1021.	2.9	20
164	Low frequency of CDKN2 mutation in endometrial carcinomas. <i>Molecular Carcinogenesis</i> , 1995, 13, 210-212.	2.7	19
165	Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines. <i>Cancer</i> , 1994, 74, 1891-1898.	4.1	23
166	Dexamethasone used as an antiemetic in chemotherapy protocols inhibits natural cytotoxic (NC) cell activity. <i>Cancer</i> , 1990, 65, 466-472.	4.1	14
167	Recurrent gestational trophoblastic disease. Experience of the southeastern regional trophoblastic disease center. <i>Cancer</i> , 1990, 66, 978-982.	4.1	88